A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study.
Fiche publication
Date publication
juin 2017
Journal
BMC cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr MENEVEAU Nathalie, Pr PIVOT Xavier, Dr VERNEREY Dewi, Dr MOUGIN-GUILLAUME Fabienne, Dr JACQUINOT Quentin
Tous les auteurs :
Jacquinot Q, Meneveau N, Chatot M, Bonnetain F, Degano B, Bouhaddi M, Dumoulin G, Vernerey D, Pivot X, Mougin F
Lien Pubmed
Résumé
The overexpression of human epidermal growth factor receptor-2 (HER2) in breast cancer is a poor prognosis. Trastuzumab improves overall survival but is associated with cardiotoxicity, especially a decline in left ventricular ejection fraction (LVEF). In addition, chemotherapy and radiotherapy increase fatigue and pain, decrease physical capacity and health-related quality of life. To date, no study has evaluated the benefits of physical activity on the side effects of treatment in patients with HER2 positive breast cancer. The aim of this study is to evaluate the impact of 3 months' exercise intervention on myocardial function and in particular on the rate of cardiotoxicity.
Mots clés
Breast cancer, Cardiotoxicity, Exercise, HER2 overexpression, Study protocol, Supportive care
Référence
BMC Cancer. 2017 Jun 19;17(1):425